J. Marruecos
4 Papers
1 Citations
J. Marruecos is an academic researcher. The author has contributed to research in topics: Standard treatment & Neoadjuvant therapy. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Pseudoprogression as an adverse event of glioblastoma therapy
Carmen Balana,Jaume Capellades,Estela Pineda,Anna Estival,Josep Puig,Sira Domenech,Eugenia Verger,Teresa Pujol,Maria Martinez-Garcia,Laura Oleaga,JoseMaria Velarde,Carlos Mesia,Rafael Fuentes,J. Marruecos,Sonia Del Barco,Salvador Villà,Cristina Carrato,Oscar Gallego,Miguel Gil-Gil,Jordi Craven-Bartle,Francesc Alameda +20 more
TL;DR: PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma, and only MGMT methylation status was associated to PsP.
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Carmen Balana,Anna Estival,Iris Teruel,M. Hardy-Werbin,Juan Manuel Sepúlveda,Estela Pineda,Maria Martinez-Garcia,Oscar Gallego,R. Luque,Miguel Gil-Gil,Carlos Mesia,S. del Barco,Ana Herrero,Alfonso Berrocal,Pedro Pérez-Segura,R. de las Peñas,J. Marruecos,R. Fuentes,Gaspar Reynes,J.M. Velarde,Andrés F. Cardona,Eugenia Verger,C Panciroli,S. Villà +23 more
TL;DR: OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy, and completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factors.
1
MGMT methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study
Anna Estival,Estela Pineda,Maria Martinez-Garcia,J. Marruecos,Carlos Mesia,A. Lucas,M. Macià,M. Gil,Oscar Gallego,Eugenia Verger,S. Del Barco,R. Fuentes,J. Craven,N. García,S. Villà,J.M. Velarde,Cristina Carrato,Teresa Ribalta,Oriol Arpí,C. Balana +19 more
1
RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma.
Anna Esteve-Codina,Francesc Alameda,Cristina Carrato,Estela Pineda,Oriol Arpí,Maria Martinez-Garcia,Mar Mallo,Marta Gut,Marc Dabad,Avelina Tortosa,Sonia Del Barco,Jaume Capellades,Josep Puig,Oscar Gallego,Teresa Pujol,Laura Oleaga,Miquel Gil-Gil,Cristian de Quintana-Schmidt,I. Valduvieco,Anna Martínez-Cardús,Beatriz Bellosillo,Ana M. Muñoz-Mármol,Anna Esteve,Marta Domenech,Angels Camins,Jordi Craven-Bartle,Salvador Villà,J. Marruecos,Sira Domenech,Núria de la Iglesia,Carmen Balana +30 more
TL;DR: Levels of expression of 13 novel genes were identified as independent prognostic markers in glioma-CpG island methylator phenotype–negative patients, independently of clinical factors and MGMT methylation, and were validated in at least one external database.